Ischemic Heart Failure Clinical Trial
Official title:
Fasting Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure
Verified date | June 2017 |
Source | Guangdong General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Current prospective cohort study is to evaluate the association between fasting lipid profiles (including total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, apolipoprotein A, apolipoprotein B and lipoprotein(a)) and fasting plasma glucose at admission with cardiovascular disease outcomes (including fatal and non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, or cardiovascular mortality) and all-cause mortality.in patients with ischemic heart failure and left ventricular ejection fraction < 45 % evaluated by echocardiography during 12 months follow-up.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1.Diagnosed as coronary artery disease by coronary angiography; 2. Left
ventricular ejection fraction < 45% evaluated by echocardiography during index
hospitalization. Exclusion Criteria: Coexistent malignant diseases; stage 3 or more of chronic kidney disease; liver dysfunction with ALT or AST higher than 3 times of normal limit range; do not want to participant in current study |
Country | Name | City | State |
---|---|---|---|
China | Guangdong General Hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangdong General Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiovascular diseases outcomes | Fatal or non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, and cardiovascular mortality | 12 months after discharge from index hospitalization | |
Secondary | All-cause mortality | All-cause mortality | 12 months after discharge from index hospitalization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02240940 -
PARACHUTE China Approval Trial
|
N/A | |
Completed |
NCT00846001 -
Resynchronization Surgery Combined Unified Efficacy
|
Phase 3 | |
Recruiting |
NCT05566600 -
Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure
|
Early Phase 1 | |
Active, not recruiting |
NCT01961726 -
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Terminated |
NCT00102128 -
Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.
|
Phase 2 | |
Not yet recruiting |
NCT03491969 -
Clinical Study of Lipoic Acid on Ischemic Heart Failure
|
Phase 4 | |
Recruiting |
NCT01555320 -
Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure
|
N/A | |
Recruiting |
NCT02875639 -
A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)
|
Phase 2 | |
Completed |
NCT02700880 -
LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry
|
||
Active, not recruiting |
NCT01643590 -
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.
|
Phase 2 | |
Active, not recruiting |
NCT02115568 -
Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203
|
N/A | |
Enrolling by invitation |
NCT01709279 -
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure
|
N/A | |
Not yet recruiting |
NCT06258447 -
CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
|
N/A |